January 2022

Tau protein, plaque, and brain waves maybe the solutions to treating the progressive condition.

Properly implemented CGMP should not be seen as a regulatory burden but a remedy to poorly compounded drugs.

Drug manufacturers participating in Medicaid offer lower prices, stretching resources and providing comprehensive services to more patients.

The FDA has approved zanubrutinib (Brukinsa, BeiGene) for the treatment of adults with Waldenström macroglobulinemia (WM).

Monoclonal antibodies and emerging agents may avert severe illness, especially for high-risk individuals.

Tisotumab vedotin-tftv is used as antitumor therapy for patients with disease progression during or after chemotherapy.

Finding ways to eliminate barriers to care helps narrow the gap.

Staffing shortage hits technician ranks hardest, putting additional pressure on pharmacists.